Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 51 to 60 of 2432 total matches.
Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
to placebo, for up to 2 RSV
seasons (see Tables 1 and 2).3-5
RSV DISEASE ― RSV typically causes a mild ...
Two recombinant vaccines, Arexvy (GSK) and
Abrysvo (Pfizer), have been approved by the FDA for
prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in adults
≥60 years old. They are the first RSV vaccines to be
approved in the US. Abrysvo is also approved for
use in pregnant women at 32-36 weeks' gestation
to prevent LRTD caused by RSV in their infants from
birth through 6 months of age.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):155-6 doi:10.58347/tml.2023.1686a | Show Introduction Hide Introduction
Lodoco: Low-Dose Colchicine for Cardiovascular Event Prevention
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
for
cardiovascular disease.1
MECHANISM OF ACTION — Inflammation is thought
to play an important role ...
Colchicine (Colcrys, and others), which has been
available in the US for decades for prophylaxis
and treatment of gout flares and other indications
in oral formulations that contain 0.6 mg of the
drug, has now been approved in 0.5-mg tablets as
Lodoco (Agepha) to reduce the risk of myocardial
infarction (MI), stroke, coronary revascularization,
and cardiovascular death in adults with established
atherosclerotic disease or multiple risk factors for
cardiovascular disease.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):156-7 doi:10.58347/tml.2023.1686b | Show Introduction Hide Introduction
Valoctocogene Roxaparvovec (Roctavian) – A Gene Therapy for Severe Hemophilia A
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
from their biosimilars.
HEMOPHILIA A ― Hemophilia A is an X-linked
genetic disorder (estimated prevalence 1:5000 live ...
Valoctocogene roxaparvovec-rvox (Roctavian –
Biomarin), an adeno-associated virus (AAV) vector-based
gene therapy, has been approved by the FDA
for one-time treatment of severe hemophilia A
in adults without pre-existing antibodies to AAV
serotype 5. It is the first gene therapy to be approved
in the US for treatment of hemophilia A.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):157-8 doi:10.58347/tml.2023.1686c | Show Introduction Hide Introduction
Delandistrogene Moxeparvovec (Elevidys) for Duchenne Muscular Dystrophy
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
, recessive,
progressive neuromuscular disorder (estimated
prevalence 1:5000 live male births) characterized ...
Delandistrogene moxeparvovec-rokl (Elevidys –
Sarepta), an adeno-associated virus (AAV) vector-based
gene therapy, has received accelerated
approval from the FDA for treatment of ambulatory
children 4-5 years old with Duchenne muscular
dystrophy (DMD) who have a confirmed mutation in
the dystrophin gene. It is the first gene therapy to be
approved in the US for treatment of DMD. Accelerated
approval was based on expression of microdystrophin
in skeletal muscle, a surrogate endpoint.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):159-60 doi:10.58347/tml.2023.1686d | Show Introduction Hide Introduction
Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
cause an estimated 58,000-80,000
hospitalizations among children ...
The FDA has approved nirsevimab-alip (Beyfortus –
AstraZeneca/Sanofi), a long-acting monoclonal
antibody, for the prevention of respiratory syncytial
virus (RSV) lower respiratory tract disease in
neonates and infants born during or entering their
first RSV season, and in children ≤24 months old who
are at increased risk for severe RSV disease through
their second RSV season. Nirsevimab is the first drug
to be approved for protection of all infants during
their first RSV season.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):145-7 doi:10.58347/tml.2023.1685a | Show Introduction Hide Introduction
Suflave — A Low-Volume Colonoscopy Preparation
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
regimens are hyperosmotic and require consumption
of 2-3 liters of fluid.1
MECHANISM OF ACTION — Suflave ...
The FDA has approved Suflave (Sebela/Braintree), a
low-volume polyethylene glycol (PEG)- and sulfate-based
product for cleansing of the colon prior to
colonoscopy in adults. Other oral colonoscopy
preparations available in the US are listed in
Table 2. Suflave is marketed as tasting better than
other products.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):148-51 doi:10.58347/tml.2023.1685b | Show Introduction Hide Introduction
Opill — An OTC Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
to effective contraception and
reduce the rate of unintended pregnancies.1
Key Points: Norgestrel (Opill ...
The FDA has approved Opill (Perrigo), a progestin-only
oral contraceptive that contains norgestrel, for
sale over the counter (OTC). Opill is the first oral
contraceptive to be approved in the US for sale without
a prescription. Approval of OTC Opill is intended
to increase access to effective contraception and
reduce the rate of unintended pregnancies.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):151-2 doi:10.58347/tml.2023.1685c | Show Introduction Hide Introduction
Elranatamab (Elrexfio) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
) was the first.1
Pronunciation Key
Elranatamab-bcmm: el’ ran a ta mab Elrexfio: el reks’ fe o
The four-letter ...
Elranatamab-bcmm (Elrexfio – Pfizer), a bispecific
B-cell maturation antigen (BCMA)-directed CD3
T-cell engager, has been granted accelerated
approval by the FDA for treatment of relapsed or
refractory multiple myeloma in adults who received
≥4 prior lines of therapy, including a proteasome
inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Accelerated approval
was based on the response rate and durability of
response. Elranatamab is the second bispecific
BCMA-directed CD3 T-cell engager to be approved for
this indication; teclistamab (Tecvayli) was the...
Med Lett Drugs Ther. 2023 Sep 18;65(1685):e153-4 doi:10.58347/tml.2023.1685d | Show Introduction Hide Introduction
Drugs for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
,
more than in any previous year.1 Several guidelines on
the management of opioid use disorder ...
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne infections such as HIV
and viral hepatitis, adverse pregnancy outcomes, and
increased mortality. According to the NIH, there were
80,411 deaths involving an opioid in the US in 2021,
more than in any previous year. Several guidelines on
the management of opioid use disorder are available;
all recommend maintenance pharmacotherapy as the
standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44 doi:10.58347/tml.2023.1684a | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
impairment
Zubsolv 5.7/1.4 mg produces
systemic buprenorphine levels
equivalent to those seen with
8 mg ...
View Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e144-5 doi:10.58347/tml.2023.1684b | Show Introduction Hide Introduction